newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

  • IGC Pharma announced new Tau-PET biomarker research to be presented at the 2026 Global Tau Conference on May 14-15, 2026, in Washington, D.C.
  • The study titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression in Amyloid-Positive APOE4 Carriers" evaluates Shannon entropy as a quantitative measure of tau pathology spatial heterogeneity.
  • Analysis utilized F-AV-1451 Tau-PET data from 931 participants and 1,570 scans sourced from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
  • Findings indicate that among amyloid-positive participants with elevated tau burden, more focal tau spreading patterns correlate with worse cognitive outcomes, faster tau accumulation, and are particularly prominent in APOE4 carriers.
  • The research suggests Shannon entropy may serve as a concise imaging-derived measure for Alzheimer's disease monitoring, patient stratification, therapeutic development.
  • IGC Pharma integrates advanced analytics, neuroimaging, AI-driven approaches to support its Alzheimer's research platform while advancing the lead asset IGC-AD1 in the Phase 2 CALMA trial for agitation.
  • The Global Tau Conference serves as an international forum for tau-related neurodegenerative diseases, reflecting IGC Pharma's engagement with the global research community.
  • IGC Pharma's pipeline includes TGR-63 targeting amyloid plaques, alongside early-stage programs focused on neurodegeneration, tau proteins, metabolic dysfunctions.